Actelion v. MSN Laboratories: Consent Judgment in Endothelin Receptor Antagonist Patent Dispute
Actelion Pharmaceuticals filed a patent infringement action in the District of New Jersey against MSN Laboratories and MSN Pharmaceuticals over US7094781B2, a patent covering sulfamides and their use as endothelin receptor antagonists. The case resolved by consent judgment within 147 days of filing, with all claims dismissed with prejudice and no costs awarded to either party.
A swift consent judgment ends Actelion's sulfamide patent dispute with MSN
Actelion Pharmaceuticals, Ltd. and its US affiliate Actelion Pharmaceuticals US, Inc. filed this patent infringement action on 20 June 2023 in the United States District Court for the District of New Jersey (Case No. 2:23-cv-03371). The defendants, MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc., are generic pharmaceutical companies. The sole patent in suit is US7094781B2, which covers sulfamides and their use as endothelin receptor antagonists — a drug class relevant to conditions such as pulmonary arterial hypertension.
The case resolved on 14 November 2023 when Judge Stanley R. Chesler signed a consent judgment dismissing all claims, counterclaims, affirmative defenses, and demands with prejudice. No costs, disbursements, or attorneys' fees were awarded to any party. The recorded basis of termination is Consent Judgment; the docket order is styled as a dismissal with prejudice under the consent judgment framework. The specific terms agreed between the parties — including any licensing or market-entry provisions — are not disclosed in the available record.
The case closed in just 147 days from filing to consent judgment, suggesting the parties reached agreement early in the litigation lifecycle, well before any substantive merits briefing would typically conclude in a pharmaceutical patent case. What drove the parties to resolution at this stage — and on what commercial terms, if any — is not apparent from the public record.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 147 days
Case resolved in 147 days — notably swift for a pharmaceutical patent infringement action in the District of New Jersey.
US7094781B2 — Sulfamides as endothelin receptor antagonists
Any company developing, manufacturing, or filing regulatory submissions for sulfamide-based endothelin receptor antagonists — or functionally related compounds — should treat US7094781B2 as a live freedom-to-operate consideration. The patent was actively enforced in 2023, resolved without a validity finding, and remains in force. Generic pharmaceutical developers, formulation teams, and ANDA filers in the pulmonary arterial hypertension space are the most directly exposed.
Official order — verbatim text
The consent judgment, signed by Judge Chesler on 14 November 2023, dismisses all claims, counterclaims, affirmative defenses, and demands with prejudice and without costs to any party. The with-prejudice disposition prevents relitigation of these specific disputes, but the order does not constitute a merits ruling on validity or infringement of US7094781B2 — the patent's enforceability against third parties is unaffected by this judgment.
Consent judgment: what the agreed resolution means for both parties
What a consent judgment means in patent litigation
A consent judgment is a binding, court-entered judgment reflecting terms agreed by the parties. It carries the full force of a judicial order — not merely a private settlement — and Judge Chesler's signature on 14 November 2023 made it enforceable by the court. All claims, counterclaims, affirmative defenses, and demands were dismissed with prejudice, meaning neither party can relitigate the same disputes in this forum.
Court-entered, binding and finalActelion secures a court-entered judgment protecting its patent position
For Actelion, the consent judgment provides a binding resolution entered by the court, formally concluding MSN's challenge without a merits finding that could undermine US7094781B2. The dismissal with prejudice prevents MSN from re-raising the same defenses or counterclaims in this action. The specific terms underlying the agreement — including any market-access provisions — are not disclosed in the available record.
US7094781B2 survives this challengeMSN exits the litigation with prejudice and no costs exposure
MSN Laboratories and MSN Pharmaceuticals secured a no-costs outcome — neither disbursements nor attorneys' fees were awarded against them. The with-prejudice dismissal closes this specific action. However, because the resolution is a consent judgment rather than a merits ruling, no judicial finding on validity or infringement of US7094781B2 is established in the public record. Any commercial terms agreed by MSN are not disclosed.
No costs; no merits findingEndothelin antagonist IP enforcement: what this signals for the sector
Consent judgments in pharmaceutical patent cases — particularly those resolved within months of filing — consistently signal that commercial considerations outweigh litigation risk for both sides. For other generic manufacturers assessing US7094781B2, the patent remains unchallenged on the merits in this action. Companies in the endothelin receptor antagonist space should treat this patent as an active enforcement risk and conduct freedom-to-operate analysis accordingly.
Active enforcement risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Actelion Pharmaceuticals, Ltd. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Actelion Pharmaceuticals US, Inc. | Company | Search in Eureka ↗ |
| Defendant | MSN Laboratories Private Limited | Company | /Search in Eureka ↗ |
| Co-Defendant | MSN Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Keith J. Miller | Attorney | Counsel for Actelion Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing Actelion Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the endothelin receptor antagonist IP space
Forward-looking patent and innovation intelligence derived from Actelion's enforcement of US7094781B2 and the broader endothelin receptor antagonist technology landscape.
Actelion's sulfamide and endothelin patent filing activity
Actelion — now part of Johnson & Johnson/Janssen — has historically maintained an extensive patent portfolio in the endothelin receptor antagonist space. Tracking their US and EP filings beyond US7094781B2 reveals the breadth of exclusionary coverage around sulfamide scaffolds and related chemical classes, signalling where the next enforcement perimeter may sit.
Actelion portfolio depthEndothelin receptor antagonist filing trends: who is patenting what
The endothelin antagonist space — covering macitentan, bosentan, and related scaffolds — has seen sustained filing activity from both innovators and generics. Mapping recent filings in this chemical class reveals whether new entrants are designing around existing IP or staking claims in adjacent structural territory relevant to pulmonary arterial hypertension and related indications.
Competitive filing trendsMSN Laboratories' patent and ANDA filing posture in cardiovascular drugs
MSN Laboratories is an active generic pharmaceutical developer with filings across cardiovascular and pulmonary drug classes. Analysing MSN's patent prosecution and ANDA submission history in these categories helps competitors and brand-name holders anticipate which products MSN is likely to target next — and where IP conflicts are most probable.
Generic challenger landscapeAdjacent sulfamide scaffolds: R&D white space near US7094781B2
US7094781B2's claims on specific sulfamide structures as endothelin receptor antagonists may leave adjacent chemical space accessible. Identifying structural analogues, alternative receptor-selectivity profiles, or next-generation scaffolds that fall outside current claim coverage represents an R&D opportunity for both innovators and formulation specialists seeking freedom to operate.
Design-around potentialSimilar patent infringement cases: endothelin antagonists and pharma consent judgments
Explore related pharmaceutical patent infringement actions in the District of New Jersey and beyond involving endothelin receptor antagonist or sulfamide compound patents.
What this case signals for the endothelin antagonist IP landscape
A 147-day consent judgment in a pharma patent case consistently suggests commercial resolution — and an undiminished patent.
US7094781B2 emerges unchallenged on the merits — treat it as live risk
No court made a finding on validity or infringement. For any generic or biosimilar developer working in the endothelin receptor antagonist space, this patent remains an active enforcement risk. FTO analysis against US7094781B2 is a baseline requirement before entering this product category.
Early resolution patterns in ANDA-adjacent cases signal strategic leverage
Cases that resolve by consent judgment within five months of filing typically indicate that one or both parties identified a commercial path preferable to full merits litigation. Companies monitoring Actelion's enforcement posture should track future filings against other generics in the same therapeutic class.
Actelion v MSN — key questions answered
The case was resolved by consent judgment entered by Judge Stanley R. Chesler on 14 November 2023. All claims, counterclaims, affirmative defenses, and demands were dismissed with prejudice, with no costs, disbursements, or attorneys' fees awarded to any party. The specific terms underlying the agreement are not disclosed in the available record.
The sole patent in suit was US7094781B2 (application number US10/433041), covering sulfamides and their use as endothelin receptor antagonists. The patent was asserted by Actelion Pharmaceuticals, Ltd. and Actelion Pharmaceuticals US, Inc. against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc.
No. A consent judgment does not constitute a merits ruling on patent validity or infringement. Because the case resolved without judicial determination of the substantive issues, US7094781B2's enforceability against third parties is unaffected. The patent remains a live enforcement risk for other companies in the endothelin receptor antagonist space.
The case was filed on 20 June 2023 and closed on 14 November 2023 — a total of 147 days. This is a notably swift resolution for a pharmaceutical patent infringement action in the District of New Jersey, suggesting the parties reached agreement early in the litigation, well before typical merits briefing would conclude.
A consent judgment with prejudice is a court-entered, binding order that prevents the named parties from relitigating the same claims. In the pharmaceutical context, it ends the specific action without a validity or infringement finding, leaving the patent's broader enforceability intact. The specific commercial terms — including any market-access or licensing arrangements — agreed between Actelion and MSN are not disclosed in the available public record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.